Why the study?
Randomized controlled trials were needed to assess the risk-benefit profile of anticoagulation in patients with device-detected atrial high-rate episodes or subclinical AF.
Do oral anticoagulants reduce ischemic stroke in patients with subclinical atrial fibrillation detected by CIEDs?
Do oral anticoagulants reduce ischemic stroke in patients with subclinical atrial fibrillation detected by CIEDs?
In patients with device-detected subclinical atrial fibrillation, oral anticoagulation reduces ischemic stroke risk but increases major bleeding, highlighting the need for shared decision-making based on individual risk profiles.
Answers are grounded in this paper and cite their sources.
May support individualized OAC decisions balancing stroke and bleeding risks; leaves open optimal patient selection for trials.
Atrial fibrillation (AF) may be asymptomatic and the extensive monitoring capabilities of cardiac implantable electronic devices (CIEDs) revealed asymptomatic atrial tachi-arrhythmias of short duration (minutes-hours) occurring in patients with no prior history of AF and without AF detection at a conventional surface ECG. Both the terms "AHRE" (Atrial High-Rate Episodes) and subclinical AF were used in a series of prior studies, that evidenced the association with an increased risk of stroke. Two randomized controlled studies were planned in order to assess the risk-benefit profile of anticoagulation in patients with AHRE/subclinical AF: the NOAH and ARTESiA trials. The results of these two trials (6548 patients enrolled, overall) show that the risk of stroke/systemic embolism associated with AHRE/subclinical AF is in the range of 1-1.2 % per patient-year, but with an important proportion of severe/fatal strokes occurring in non-anticoagulated patients. The apparent discordance between ARTESiA and NOAH results may be approached by considering the related study-level meta-analysis, which highlights a consistent reduction of ischemic stroke with oral anticoagulants vs. aspirin/placebo (relative risk [RR] 0.68, 95 % CI 0.50-0.92). Oral anticoagulation was found to increase major bleeding (RR 1.62, 95 % CI 1.05-2.5), but no difference was found in fatal bleeding (RR 0.79, 95 % CI 0.37-1.69). Additionally, no difference was found in cardiovascular death or all-cause mortality. Taking into account these results, clinical decision-making for patients with AHRE/subclinical AF at risk of stroke, according to CHA₂DS₂-VASc, can now be evidence-based, considering the benefits and related risks of oral anticoagulants, to be shared with appropriately informed patients.
No takes yet. Share an insight, caveat, or question.
Boriani et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: